Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 139-142

  Usmani, Saad ^a   Sexton, Rachel ^b   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; RITUXIMAB; THALIDOMIDE;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953723177     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.032     Document Type: Conference Paper

References (12)

1. Groves FD, Travis LB, Devesa SS, et al. Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994.Cancer 1998; 82:1078.
2. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575.
3. Carbone P, Caradonna F, Granata G, et al. Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Cancer Genet Cytogenet 1992; 61:147.
4. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 2001; 116:543.
5. Wong KF, So CC, Chan JC, et al. Gain of chromosome 3/3q in B-cell chronic lymphoproliferative disorder is associated with plasmacytoid differentiation with or without IgM overproduction. Cancer Genet Cytogenet 2002; 136:82.
6. Rivera AI, Li MM, Beltran G, et al. Trisomy 4 as the sole cytogenetic abnormality in a Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 2002; 133:172.
7. Han T, Sadamori N, Takeuchi J, et al. Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: Significance of trisomy 12.Blood 1983; 62:525.
8. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996.
9. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852.
10. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003).Blood 2001; 98:41.
11. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003; 30:116.
12. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:2227-32